Pacific Biosciences
PACB
268 hedge funds and large institutions have $1.01B invested in Pacific Biosciences in 2024 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 93 increasing their positions, 70 reducing their positions, and 51 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 70
20% more call options, than puts
Call options by funds: $8.01M | Put options by funds: $6.66M
4% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 51
2% less funds holding
Funds holding: 274 → 268 (-6)
9.88% less ownership
Funds ownership: 109.21% → 99.33% (-9.9%)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
65% less capital invested
Capital invested by funds: $2.86B → $1.01B (-$1.86B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$55.7M |
| 2 |
Bank of New York Mellon
New York
|
+$38M |
| 3 |
Millennium Management
New York
|
+$14.1M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$10.5M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$119M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$29.8M |
| 4 |
DC
Decheng Capital
Menlo Park,
California
|
-$28.8M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$24M |
PACB Hedge Fund Activity: Q1 2024 in Review
268 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2024, worth a combined $1.01B — down 65% from $2.86B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of PACB and 49 opened new positions — a net loss of 2 holders — while 70 trimmed existing stakes and 93 added.
The largest buyer was Edmond de Rothschild Holding, adding an estimated $55.7M. The largest seller was Morgan Stanley, cutting an estimated $119M.
- 268 institutional investors held Pacific Biosciences (PACB) as of Q1 2024, down from 274 in Q4 2023.
- Funds reported $1.01B of Pacific Biosciences stock for Q1 2024, down 65% quarter-over-quarter.
- 49 funds opened new Pacific Biosciences positions in Q1 2024 and 51 closed out, a net change of -2 holders.
- The largest Pacific Biosciences buyer in Q1 2024 was Edmond de Rothschild Holding, an estimated $55.7M added.
- The largest Pacific Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $119M sold.
Based on aggregated 13F filings for Q1 2024.